相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13C magnetic resonance spectroscopy study
Desiree Abdurrachim et al.
DIABETES OBESITY & METABOLISM (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat
Chih-Chao Yang et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Cardioprotective effects of CYP-derived epoxy metabolites of docosahexaenoic acid involve limiting NLRP3 inflammasome activation
Ahmed M. Darwesh et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2019)
Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction
Kim A. Connelly et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
SGLT2 Inhibitors Suppress NLRP3 Inflammasome Activity via Changes in Ketones and Insulin in Type 2 Diabetes and Cardiovascular Diseases
Yong-Ho Lee et al.
DIABETES (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Empagliflozin directly improves diastolic function in human heart failure
Steffen Pabel et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes
Julian Mustroph et al.
ESC HEART FAILURE (2018)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors
Javed Butler et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
Tsung-Ming Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
Xingjuan Shi et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition The Search for the Sweet Spot in Heart Failure
Subodh Verma et al.
JAMA CARDIOLOGY (2017)
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor
Yumei Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
Resveratrol improves exercise performance and skeletal muscle oxidative capacity in heart failure
Miranda M. Sung et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2017)
Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression
Rujun Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
Javad Habibi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
Hiroaki Kusaka et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Normalization of cardiac substrate utilization and left ventricular hypertrophy precede functional recovery in heart failure regression
Nikole J. Byrne et al.
CARDIOVASCULAR RESEARCH (2016)
Empagliflozin's Fuel Hypothesis: Not so Soon
Gary D. Lopaschuk et al.
CELL METABOLISM (2016)
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Hiddo J. L. Heerspink et al.
CIRCULATION (2016)
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
Tim Heise et al.
CLINICAL THERAPEUTICS (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
Subodh Verma et al.
DIABETES CARE (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Giuseppe Daniele et al.
DIABETES CARE (2016)
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar et al.
DIABETOLOGIA (2016)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives
Nils Bruun Jorgensen et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2016)
The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice
Weiling Leng et al.
MEDIATORS OF INFLAMMATION (2016)
Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction
Constantijn Franssen et al.
JACC-HEART FAILURE (2016)
Type 2 Diabetes and Heart Failure: Challenges and Solutions
Merlin C. Thomas
CURRENT CARDIOLOGY REVIEWS (2016)
Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
Elisa Benetti et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside
Sunder Mudaliar et al.
DIABETES CARE (2015)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2015)
Effects of Thiazide-Type and Thiazide-Like Diuretics on Cardiovascular Events and Mortality Systematic Review and Meta-Analysis
Rik H. G. Olde Engberink et al.
HYPERTENSION (2015)
Lowering blood pressure in diabetes
Seema Kang
LANCET DIABETES & ENDOCRINOLOGY (2015)
The Importance of NLRP3 Inflammasome in Heart Failure
Brittany Butts et al.
JOURNAL OF CARDIAC FAILURE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Localizations of Na+-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
Ivana Vrhovac et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2015)
Resveratrol Treatment of Mice With Pressure-Overload-Induced Heart Failure Improves Diastolic Function and Cardiac Energy Metabolism
Miranda M. Sung et al.
CIRCULATION-HEART FAILURE (2015)
Blood Pressure Lowering in Type 2 Diabetes A Systematic Review and Meta-analysis
Connor A. Emdin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury
Yi Liu et al.
BASIC RESEARCH IN CARDIOLOGY (2014)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Bowen Lin et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
S. Macha et al.
DIABETES OBESITY & METABOLISM (2014)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J. Bolinder et al.
DIABETES OBESITY & METABOLISM (2014)
Fibrosis and heart failure
Ana Maria Segura et al.
HEART FAILURE REVIEWS (2014)
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats
Atsuo Tahara et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2014)
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Martin Ridderstrale et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
Florian Gembardt et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
Timo Rieg et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers
Christian Friedrich et al.
CLINICAL THERAPEUTICS (2013)
Lack of drug-drug interaction between empagliflozin, asodium glucose cotransporter 2 inhibitor, and warfarin inhealthy volunteers
S. Macha et al.
DIABETES OBESITY & METABOLISM (2013)
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
T. Heise et al.
DIABETES OBESITY & METABOLISM (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects
Akiko Sarashina et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Atsuo Tahara et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers
Sreeraj Macha et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
Eiji Kurosaki et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Tim Heise et al.
DIABETES THERAPY (2013)
Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers
Tobias Brand et al.
ADVANCES IN THERAPY (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
Critical role for calcium mobilization in activation of the NLRP3 inflammasome
Tomohiko Murakami et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart
Esther E. Creemers et al.
CARDIOVASCULAR RESEARCH (2011)
Mechanistic connection between inflammation and fibrosis
Soo Bong Lee et al.
KIDNEY INTERNATIONAL (2010)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Inflammatory Biomarkers in Heart Failure Revisited: Much More than Innocent Bystanders
Stephan von Haehling et al.
Heart Failure Clinics (2009)
Resolution of inflammation: state of the art, definitions and terms
Charles N. Serhan et al.
FASEB JOURNAL (2007)
Development of heart failure in chronic hypertensive Dahl rats - Focus on heart failure with preserved ejection fraction
S Klotz et al.
HYPERTENSION (2006)
Health outcomes associated with various antihypertensive therapies used as first-line agents - A network meta-analysis
BN Psaty et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Upregulation of interleukin-18 expression in mouse primary keratinocytes induced to differentiate by calcium
J Kong et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2002)
Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats
R Doi et al.
JOURNAL OF HYPERTENSION (2000)
分享论文
